Lord Appointed to National Advisory Council

Jack Lord, M.D., Humana's chief innovation officer, was invited recently by Tommy G. Thompson, secretary of Health and Human Services, to serve on the National Advisory Council for Healthcare Research and Quality.

The National Advisory Council for Healthcare and Quality advises the United States Department of Health and Human Services and the Agency for Healthcare Research and Quality (AHRQ) on actions that enhance quality, improve the outcomes and reduce the cost of health care services. The council also focuses on improving access to and utilization of health care services through scientific research and improvements in clinical practice and in the organization, financing and delivery of service.

"The work done by AHRQ exemplifies the impact of research translated into practice," said Lord. "It's an honor to serve on such a prestigious council with the pre-eminent thought leaders in the field. My role with the council will allow me to strengthen my personal commitment to ensuring access to affordable, quality health care in the United States."

This prestigious, three-year appointment places Lord among only 21 distinguished health care leaders who serve on this important council. His three-year term began on November 1, 2002.

Back to top

 

Lord Receives DMAA Award

Jack Lord (right), M.D., Humana's chief innovation officer, receives the Karen Coughlin Award from DMAA.

In November 2002, the Disease Management Association of American (DMAA) announced that Jack Lord, Humana’s chief innovation officer, is this year's recipient of the Karen Coughlin Individual Disease Management Leadership Award.

DMAA is a nonprofit, voluntary membership organization created in response to the need for a single voice and a more scientific approach to the measurement of the success of disease management programs. Under Lord’s leadership from 2001 to 2002, the DMAA restructured its board, increased its domestic membership to include all major national health insurers, nearly doubled its resources and, with new chapters in Australia, Singapore and Europe, spawned an international movement toward disease management and evidence-based care.

One of only two individual awards given as part of the Recognizing Excellence Awards Program, the Karen Coughlin award honors Lord for his contributions to advancements in the care of the millions of U.S. citizens with chronic disease.

"Disease management is increasingly being recognized as one of the most important tools we have to proactively deal with chronic disease in this country. All of us in the health care community deserve recognition for our hard work in addressing the multiple issues of disease management," said Lord.

Back to top

Humana Changes CAD Program

Some changes were made to Humana's Coronary Artery Disease (CAD) program when Humana renewed its contract for disease management services with CorSolutions Inc. in October 2002.

Members of all acuity levels were eligible to participate in the former CAD program. However, under the new CAD program, participation is restricted to high-acuity members who require the most attention and support. In addition, participation in the program is now limited to nine months. Humana will identify high-acuity participants through a combination of factors, such as diagnosis, age, co-morbidities and utilization history. Low- and moderate-acuity CAD members and high-acuity members who had participated in the program for nine months were transitioned out of the program in November and December.

Humana's Congestive Heart Failure (CHF) program, which also is provided by CorSolutions, remains focused on high-acuity New York Heart Association Class III and IV patients who may stay in the program as long as they meet eligibility requirements. Those requirements include, but are not limited to, enrollment in a Humana plan as a primary health plan, remaining a Class III or IV CHF patient and the absence of certain co-morbid conditions.

If you have questions about these changes or want more information about the CAD and CHF programs, please call your local Humana medical director.

Back to top

 

 

 

 

 



Letter from Jack Lord
Using In-network Physicians and Other Care
 Providers Reduces Costs 
Grievances & Appeals Moves to Service Centers
The Leapfrog Group Initiative Making Inroads
FDA Approves Claritin as OTC Medication
Lord Appointed to National Advisory Council
Lord Receives DMAA Award
Humana Changes CAD Program
Ask an Expert
Staff Incentives Can Boost Morale - Inexpensively